CRF Health’s TrialMax Touch® Solution Selected for Landmark Global Oncology Study
Plymouth Meeting, PA-October 26, 2017-CRF Health, a global provider of patient-centered eSource technology and service solutions for the life sciences industry, announced that its TrialMax Touch® solution has been selected by a top ten pharmaceutical company for a landmark global oncology trial. The three year study marks CRF Health’s involvement in over 115 oncology studies which have realized the benefits of electronically collected eCOA data, and aims to better understand patients’ quality of life post-treatment. The trial will involve more than 1,000 patients across 200 sites in 20 countries.
CRF Health will be providing an adapted version of TrialMax Touch, an easy-to-use smartphone solution, to all patients in the study. The solution was selected by the sponsor for the benefits it brings, such as streamlining data collection by instantly capturing data rather than waiting for patients to visit the sites, and a high compliance rate which is achieved through the solutions’ notification reminders, intuitive interface, and mobility. TrialMax Touch makes it simpler and quicker for the patients, and ultimately brings an increased insight into Patient Reported Outcomes (PROs).
“Historically, capturing quality data in the post progression stage can be a major challenge for sponsors, and burdensome for subjects. CRF Health was deemed to be the best equipped to help ease this burden and maximize the results of the trial for a number of reasons, including their ability to make paper backups obsolete,” commented John Blakeley, Chief Business Officer at CRF Health.
“Many factors such as disease progression or adverse reactions can create difficulty for subjects to make it to their scheduled site visits. This creates a problem for sponsors that would typically require changes to the PRO assessment schedules” further comments Blakeley. “We’re delighted that our TrialMax Touch solution has helped overcome this challenge by streamlining the data collection process to the point where it eliminates the need for patients to make on-site visits simply to capture data.”
For further information on CRF Health, please visit http://www.crfhealth.com
About CRF Health
CRF Health is a provider of patient-centered eSource and telemedicine technologies and service solutions for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® platform consistently demonstrates data accuracy, patient and site compliance, and patient retention. Its recent acquisition of mHealth provider Entra Health, has allowed CRF Health to extend the connectivity of its existing technology to now include cloud-based remote patient monitoring, telehealth, data exchange, and analytics.
CRF Health’s eSource solutions improve trial engagement by making the patient the center piece of the healthcare and clinical trial process, and seamlessly integrating into sites to maximize protocol compliance. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent™, an electronic solution for collecting informed consent in clinical trials.
Contact: media@crfhealth.com, +1 267.498.2350
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
